By Joshua Kirby

Novartis AG said Monday that it is appointing Gilbert Ghostine to chair the board of directors of its generics division Sandoz, which the drug maker is in the process of spinning off.

Mr. Ghostine has been chief executive of Geneva-based perfume maker Firmenich since 2014 and previously also held executive positions at drinks group Diageo PLC, Novartis said. He will become chairman of the Sandoz board following board and shareholder approval, the Swiss company said.

Novartis last year set out a plan to strip away Sandoz and focus on its core business, a process set to be completed in the second half of this year.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

(END) Dow Jones Newswires

February 20, 2023 01:43 ET (06:43 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Novartis.